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EssentialsBleeding risks for nonsyndromic platelet function disorders (PFDs) are unknown.We examined bleeding in PFDs and its relationship to certain laboratory findings.Nonsyndromic PFD had 4‐ to 207‐fold increased risk of bleeding.Bleeding symptom differed between severe dense granule deficiency and impaired collagen aggregation.

1. INTRODUCTION {#rth212374-sec-0007}
===============

Platelet function disorders (PFDs) are important causes of bleeding.[^1^](#rth212374-bib-0001){ref-type="ref"} The molecular causes of many rare, severe, and syndromic PFDs and thrombocytopenic disorders are now defined.[^2^](#rth212374-bib-0002){ref-type="ref"}, [^3^](#rth212374-bib-0003){ref-type="ref"} PFDs that present with impaired maximal aggregation (MA) responses to multiple agonists by light transmission aggregometry (LTA)[^4^](#rth212374-bib-0004){ref-type="ref"}, [^5^](#rth212374-bib-0005){ref-type="ref"}, [^6^](#rth212374-bib-0006){ref-type="ref"} and/or dense granule (DG) deficiency (DGD) by whole mount electron microscopy (EM)[^7^](#rth212374-bib-0007){ref-type="ref"} are largely uncharacterized disorders, with a minority caused by mutations in transcription factors (TF), such as *RUNX1* and *FLI1*.[^8^](#rth212374-bib-0008){ref-type="ref"}, [^9^](#rth212374-bib-0009){ref-type="ref"}

Uncharacterized PFDs that impair LTA and/or cause nonsyndromic DGD are known to increase bleeding scores, assessed by bleeding history assessment tools (BAT), such as the ISTH‐BAT.[^10^](#rth212374-bib-0010){ref-type="ref"}, [^11^](#rth212374-bib-0011){ref-type="ref"}, [^12^](#rth212374-bib-0012){ref-type="ref"}, [^13^](#rth212374-bib-0013){ref-type="ref"} Recently, we illustrated a proof of principle: that odds ratio (OR) analyses could be used to estimate the bleeding risks for such PFD, using data for a family with 6 affected individuals and a cohort of general population controls.[^12^](#rth212374-bib-0012){ref-type="ref"} We now extend these bleeding risk analyses to a larger, consecutive‐case cohort with uncharacterized PFDs, with exploration for potential relationships between symptoms and laboratory findings.

2. MATERIALS AND METHODS {#rth212374-sec-0008}
========================

The study was conducted in accordance with the recently revised Declaration of Helsinki, with approval of the Hamilton Integrated Research Ethics Board (HiREB) and written informed consent of participants.

Index cases were recruited from a historic, consecutive case cohort, evaluated at Hamilton Health Sciences between September 2012 and March 2018, and diagnosed with an uncharacterized, nonsyndromic PFD after testing by the Hamilton Regional Laboratory Medicine Program. None had prior molecular testing. Inclusion criteria were: Confirmed LTA abnormalities, with reduced MA responses with ≥2 agonists (based on validated reference intervals for normal and low‐platelet‐count samples[^5^](#rth212374-bib-0005){ref-type="ref"}, [^6^](#rth212374-bib-0006){ref-type="ref"}, [^14^](#rth212374-bib-0014){ref-type="ref"}) not due to well‐characterized PFD such as Glanzmann's thrombasthenia or Bernard Soulier syndrome, and/orConfirmed DGD with \<4.9 DG/platelet, based on whole mount EM.[^7^](#rth212374-bib-0007){ref-type="ref"}

Cases with abnormal platelet ATP release without DGD or LTA abnormalities were excluded.[^13^](#rth212374-bib-0013){ref-type="ref"}

To minimize bias, relatives (affected and unaffected) of index cases were also recruited, which required assessments at Hamilton. Participants were asked to indicate on their consent if their physician should be notified if potential disease‐causing mutations were discovered. In consideration of ethical concerns,[^15^](#rth212374-bib-0015){ref-type="ref"} a revised HiREB‐approved consent was used for further recruitment when families were found to have a probable disease‐causing PFD mutation with other health implications (eg, leukemia).

The cohort included a previously reported family with a *RUNX1* frameshift mutation.[^12^](#rth212374-bib-0012){ref-type="ref"} General population controls with no history of bleeding (n = 60) were recruited.

2.1. Clinical laboratory data {#rth212374-sec-0009}
-----------------------------

Medical record data collected included hemoglobin; platelet counts; mean platelet volume (MPV); prothrombin times/International Normalized Ratio; activated partial thromboplastin times; thrombin times; Clauss fibrinogen; VWD screen findings, with "low" von Willebrand factor (VWF) defined as 0.30‐0.49 U/mL VWF antigen and a similar reduction in VWF activity[^16^](#rth212374-bib-0016){ref-type="ref"}; MA responses (assessed as described[^5^](#rth212374-bib-0005){ref-type="ref"}, [^6^](#rth212374-bib-0006){ref-type="ref"}) to 2.5 and 5.0 µmol/L ADP, 1.25 and 5.0 µg/mL Horm collagen, 6.0 µmol/L epinephrine, 1.6 mmol/L arachidonic acid (AA), 1.0 µmol/L thromboxane analogue U46619 (U46619), and 0.5 and 1.25 mg/mL ristocetin; mean DG numbers per platelet (assessed as described[^6^](#rth212374-bib-0006){ref-type="ref"}, [^7^](#rth212374-bib-0007){ref-type="ref"}, [^17^](#rth212374-bib-0017){ref-type="ref"}, [^18^](#rth212374-bib-0018){ref-type="ref"}); ABO blood group; ferritin; and ATP release by lumiaggregometry,[^13^](#rth212374-bib-0013){ref-type="ref"} if available.

2.2. Bleeding history assessment {#rth212374-sec-0010}
--------------------------------

Bleeding histories were evaluated using ISTH‐BAT[^10^](#rth212374-bib-0010){ref-type="ref"} and Clinical History Assessment Tool -- Platelets (CHAT‐P),[^12^](#rth212374-bib-0012){ref-type="ref"} with comparison to general population controls (whose BAT data was previously published[^7^](#rth212374-bib-0007){ref-type="ref"}, [^12^](#rth212374-bib-0012){ref-type="ref"}, [^13^](#rth212374-bib-0013){ref-type="ref"}) and review by 1‐2 hematologists, who cross‐checked information against medical histories. Participants were contacted if details needed clarification. Discrepancies in BAT scores and affection status (obtained by medical record review) were resolved by consensus.[^12^](#rth212374-bib-0012){ref-type="ref"}, [^13^](#rth212374-bib-0013){ref-type="ref"}

2.3. Analysis of platelet biomarkers {#rth212374-sec-0011}
------------------------------------

Samples from participants that provided additional sample donations were used to analyze platelet MYH10, and for cases with *RUNX1* sequence variants, platelet transcript levels for several RUNX1‐regulated genes. MYH10 was assessed by immunoblotting, as described[^12^](#rth212374-bib-0012){ref-type="ref"}, [^19^](#rth212374-bib-0019){ref-type="ref"} using 30 μg total platelet protein/lane (60‐90 μg on ≥2 samples if suspected to be falsely negative) and known normal and abnormal controls.[^12^](#rth212374-bib-0012){ref-type="ref"} Platelet *MYH10*, *PF4*, *MYL9*, and *ALOX12* transcript levels (cDNA prepared as described[^20^](#rth212374-bib-0020){ref-type="ref"}) were assessed at the Centre for Applied Genomics, using the QX200 Droplet Digital PCR (dPCR) system with QuantaSoft v1.7.4 (Bio‐Rad Laboratories, Hercules, CA, USA) and duplex reaction mixes of 10 μL of 2× dPCR SuperMix for Probes (Bio‐Rad Laboratories), 1 μL of the target assay (FAM labeled Taqman probes: *MYH10* Hs00413181_m1, *MYL9* Hs00382913_m1, *ALOX12* Hs00167524_m1, *PF4* HS00236998_m1; Life Technologies, Rockville, MD, USA), 1 μL of the endogenous control assay (*PPIA* probe Hs99999904_m1, VIC label; Life Technologies), 5.5 μL of nuclease‐free water, and 2.5 μL of platelet cDNA (in parallel with no template, no reverse transcriptase and Human Universal RNA controls), with cycling conditions of: 95°C for 10 minutes, 45 cycles of 94°C for 30 seconds, 58°C for 1 minute, 98°C for 10 minutes, and finally a 10°C hold on a Veriti thermal cycler (Life Technologies).

2.4. Genomic DNA isolation, whole exome and Sanger sequencing, and variant annotation {#rth212374-sec-0012}
-------------------------------------------------------------------------------------

Peripheral blood genomic DNA (300 ng) was prepared for whole exome sequencing (WES) of index cases at the Genetic Molecular Epidemiology Laboratory, using the Illumina Hiseq1500 (2 × 100 bp reads) and TruSeq Exome Capture kit (Catalog \# FC‐930‐1012) as described[^12^](#rth212374-bib-0012){ref-type="ref"} (F1 cases only), or Ion Torrent sequencing technology (1 × 125 bp reads) and the Ampliseq Exome Enrichment kit (Catalog A38262). Raw sequence reads were aligned to the human genome reference sequence (version hg19) using the Torrent Mapping Alignment Program, variant calling was performed using the Torrent Variant Calling (version 5.0.3) pipeline, and poor‐quality variants were filtered out according to the schema described by Damiati et al.[^21^](#rth212374-bib-0021){ref-type="ref"}

"Annovar" (release date: February 1, 2016) was used to annotate variant sequence change effects based on RefGene transcript boundaries.[^22^](#rth212374-bib-0022){ref-type="ref"} Only rare nonsynonymous sequence variants within bleeding‐associated genes were examined. Rare sequence variants were defined as those having a minor allele frequency (MAF) of \<0.01 within both external databases (including the National Heart, Lung, and Blood Institute GO Exome Sequencing Project, the 1000 Genomes project phase 3, and the genome Aggregation Database r2.0.2) and internal databases (from \~1000 samples sequenced from both Ion Torrent and Illumina systems). A MAF threshold of 0.01 was applied within each major ethnic strata of external databases (Europeans, Africans, Latin Americans, East Asians, South Asians) such that if a variant was common (MAF ≥ 0.01) in even a single ethnic group, it was excluded. Nonsynonymous sequence variants included missense, stopgain, stoploss, splicing, and insertion/deletion mutations. Sequencing data was examined for mutations in 63 genes associated with inherited PFD (genes listed in Megy et al[^2^](#rth212374-bib-0002){ref-type="ref"} Lentaigne et al,[^3^](#rth212374-bib-0003){ref-type="ref"} and Heremans and Freson[^23^](#rth212374-bib-0023){ref-type="ref"} including *IZKF5*), and for these genes, average read depth was 117× (standard deviation \[SD\] = 58×) across all target exons and 89.2% (SD = 14%) had high sequencing depth (\>20×), with *RUNX1* and *FLI1* sequenced at average depths of 170× and 142×, respectively. Variants were reviewed by multiple individuals to adjudicate variant pathogenicity, with rare protein‐altering sequence variants within the relevant genes assessed using the Mendelian Clinically Applicable Pathogenicity scheme.[^24^](#rth212374-bib-0024){ref-type="ref"} Probable pathogenic sequence variants and variants of uncertain significance (VUS) were further evaluated by PCR and Sanger sequencing by the MOBIX Laboratory[^12^](#rth212374-bib-0012){ref-type="ref"} (Appendix [S1](#rth212374-sup-0001){ref-type="supplementary-material"} lists primers). Copy number variation calling was performed for all samples using the eXome Hidden Markov Model method.[^25^](#rth212374-bib-0025){ref-type="ref"}

2.5. Statistical analyses {#rth212374-sec-0013}
-------------------------

The most recent laboratory results and presenting ferritins were analyzed. Two‐tailed Mann Whitney tests were used for 2 group comparisons, 1‐way analysis of variance was used for multiple group comparisons, chi‐squared tests were used to assess proportional differences, and Fisher's exact test was used when cell counts were \<5. CHAT‐P data were used to estimate bleeding risks as ORs with 95% confidence intervals (CIs), after adding 0.5 to all contingency table cells with 0 values, as described,[^12^](#rth212374-bib-0012){ref-type="ref"} with separate analysis of (i) each sex for symptoms showing sex differences among affected individuals and (ii) families with ≥5 affected individuals. Relationships between bleeding symptoms and LTA findings and/or DG counts were evaluated using Mann‐Whitney tests, chi‐squared tests, and multiple logistic regressions. *P* values \< .05 were considered statistically significant.

3. RESULTS {#rth212374-sec-0014}
==========

Most (23/24) eligible index cases consented to participate. After recruiting relatives, the cohort included 37 persons with PFD (median 2/family, range: 1‐6/family; 11 sole participants; 11% children; laboratory finding details in Table [S1](#rth212374-sup-0001){ref-type="supplementary-material"}) and 23 unaffected relatives (median 2/family, range: 0‐6/family; 17% children; none with multiple aggregation defects; n = 1 classified as unaffected with a borderline DG count \[4.6/platelet\], suggestive of a false positive,[^7^](#rth212374-bib-0007){ref-type="ref"} declined further testing). Their ages and sex distribution resembled controls (Appendix [S2](#rth212374-sup-0001){ref-type="supplementary-material"}).

3.1. Clinical laboratory findings {#rth212374-sec-0015}
---------------------------------

Most PFD participants (30/37, 81%) had normal platelet counts (Figure [1A](#rth212374-fig-0001){ref-type="fig"}, Table [S1](#rth212374-sup-0001){ref-type="supplementary-material"}), MPV similar to unaffected relatives (Appendix [S2](#rth212374-sup-0001){ref-type="supplementary-material"}), and reduced MA with multiple agonists (29/36, 81%; details in Table [S1](#rth212374-sup-0001){ref-type="supplementary-material"}), commonly with 1.0 μmol/L U46619 (74%), 1.6 mmol/L AA (62%), and/or 1.25 μg/mL collagen (60%) (Figure [1B](#rth212374-fig-0001){ref-type="fig"}). Among the 11 with confirmed DGD (Figure [1A](#rth212374-fig-0001){ref-type="fig"}, Table [S1](#rth212374-sup-0001){ref-type="supplementary-material"}), 36% had abnormal LTA, and 88% (n = 3 not tested) had impaired ATP release with ≥2 agonists. Appendix [S2](#rth212374-sup-0001){ref-type="supplementary-material"} summarizes additional laboratory findings.

![Platelet findings for the cohort of participants with an uncharacterized platelet function disorder. Blue shading indicates the range of normal results, dashed lines denote the lower limit of the reference interval (RI), closed symbols denote index cases, and open symbols denote nonindex cases. (A) Platelet counts (RI, 150‐450 × 10^9^/L) and average numbers of dense granules/platelet (lower limit of RI, 4.9). (B) Light transmittance platelet aggregometry findings, shown as the percent maximal aggregation (MA) in responses to 2.5 and 5.0 µmol/L ADP, 1.25 and 5.0 µg/mL Horm collagen, 6.0 µmol/L epinephrine, 1.6 mmol/L arachidonic acid (AA), 1.0 µmol/L U46619, and 1.25 mg/mL ristocetin. The percentage of the cohort with impaired MA is shown for each agonist.](RTH2-4-799-g001){#rth212374-fig-0001}

3.2. Findings for whole exome sequencing and biomarker analysis {#rth212374-sec-0016}
---------------------------------------------------------------

Whole exome sequencing (summarized in Tables [S2](#rth212374-sup-0001){ref-type="supplementary-material"} and [S3](#rth212374-sup-0001){ref-type="supplementary-material"}) indicated the index cases for 2 families (Caucasian) had probable pathogenic *RUNX1* sequence variants predictive of haploinsufficiency, including (i) family 1, with a *RUNX1* frameshift mutation shared by 6 affected individuals[^12^](#rth212374-bib-0012){ref-type="ref"} (1 who since developed leukemia); and (ii) family 8 with a different, novel *RUNX1* frameshift mutation (chr21:g. 36231795_36231796delTG) (protein: RUNX1: p.Thr196 SerfsTer16) shared by mother and son; her other son had a PFD with thrombocytopenia (deceased, unrelated cause; family history otherwise negative). Platelets from affected members of these 2 families showed reduced expression of the RUNX1 target genes *PF4*, *MYL9*, and *ALOX12* (Figure [S1](#rth212374-sup-0001){ref-type="supplementary-material"}) and increased *MYH10* expression, but the findings for some overlapped controls (Figure [S1](#rth212374-sup-0001){ref-type="supplementary-material"}). Although 5 of 6 cases with *RUNX1* haploinsufficiency mutations had increased platelet MYH10 protein, one was consistently negative (Figure [S2](#rth212374-sup-0001){ref-type="supplementary-material"}). The family 21 index case (sole participant, negative family history of blood problems) had increased MYH10 protein (Figure [S2](#rth212374-sup-0001){ref-type="supplementary-material"}) but was classified as having a *RUNX1* VUS (Table [S2](#rth212374-sup-0001){ref-type="supplementary-material"}) based on normal platelet transcript levels for *PF4,* *MYL9,* *ALOX12,* and *MYH10* (Figure [S1](#rth212374-sup-0001){ref-type="supplementary-material"}). Platelet MYH10 was increased in 2 of 4 cases from family 2 (Figure [S2](#rth212374-sup-0001){ref-type="supplementary-material"}), with an uncharacterized PFD, but no identified *RUNX1* or *FLI1* sequence changes. The family 5 index case had DGD, a *FLI* VUS (Table [S2](#rth212374-sup-0001){ref-type="supplementary-material"}) without detectable MYH10 (Figure [S2](#rth212374-sup-0001){ref-type="supplementary-material"}), and deletion of 1 copy of *AP3D1* (Table [S3](#rth212374-sup-0001){ref-type="supplementary-material"}) without other features of Hermansky Pudlak syndrome associated with *AP3D1* mutations.[^26^](#rth212374-bib-0026){ref-type="ref"}, [^27^](#rth212374-bib-0027){ref-type="ref"} Other index cases did not have identified mutations in PFD genes.

3.3. Bleeding scores {#rth212374-sec-0017}
--------------------

PFD participants had higher ISTH‐BAT scores than unaffected relatives and general population controls (respective medians: 9 vs 1 vs 0; *P* \< .001) (Figure [2A,B](#rth212374-fig-0002){ref-type="fig"}). ISTH‐BAT scores showed no association to age (*R* ^2^ = .28, *P* = .23); however, only four affected individuals were children. Affected females had higher ISTH‐BAT scores than affected males (respective medians: 11.5 vs 4.0; ranges: 1‐20 vs 0‐9; *P* = .002), even after excluding female‐specific items (respective medians: 8.5 vs 4; ranges: 1‐15 vs 0‐9; *P* = .002), reflecting more cutaneous bleeding (respective medians: 3 vs 0; all ranges: 0‐3; *P* = .039). ISTH‐BAT scores were higher for index compared to nonindex PFD cases (respective medians, ranges: 9 vs 6.5, 3‐15 vs 0‐9, *P* = .001; females only: 12.5 vs 7.5, 6‐20 vs 6‐11; *P* = .02; males only: 5.5 vs 3; ranges 0‐9 vs 3‐4; *P* = .22) and for PFD participants with prior surgery (medians: 9.5 vs 4; ranges: 0‐20 vs 1‐9; *P* = .024) and/or wound healing problems (medians: 10.5 vs 8; ranges: 4‐18 vs 0‐15; *P* = .022).

![ISTH‐BAT data for the cohort with an uncharacterized platelet function disorder. (A) Bleeding scores are compared for general population controls (n = 60), and unaffected (n = 23) and affected (n = 37) family members. Red closed and open symbols, respectively, indicate index and nonindex PFD cases. Circles and squares, respectively, indicate females and males. (B) Details of the ISTH‐BAT scores for PFD participants, shown as the percentages that reported bleeding symptoms by category and severity (4 indicates the most severe, 1 indicates the least severe). None reported "Other bleedings." BAT, bleeding history assessment tool; CNS, central nervous system; GI, gastrointestinal; PFD, platelet function disorder](RTH2-4-799-g002){#rth212374-fig-0002}

3.4. Bleeding risk estimates {#rth212374-sec-0018}
----------------------------

Figure [3](#rth212374-fig-0003){ref-type="fig"} summarizes the estimated risks for important mucocutaneous and challenge‐related bleeding symptoms (full details in Table [S4](#rth212374-sup-0001){ref-type="supplementary-material"}; analyses by sex in Tables [S5](#rth212374-sup-0001){ref-type="supplementary-material"} and [S6](#rth212374-sup-0001){ref-type="supplementary-material"}; family 2 estimates in Table [S7](#rth212374-sup-0001){ref-type="supplementary-material"} \[Figure [S3](#rth212374-sup-0001){ref-type="supplementary-material"} shows pedigree\]). Compared to general population controls, participants with PFD had increased risks for receiving transfusions for bleeding (OR, 100) and for prolonged nosebleeds (OR, 28); bleeding from minor wounds lasting \>1 hour (OR, 44); wound healing problems (OR, 15); excessive oral or dental bleeding (OR, 43); bleeding from operation(s) (OR, 20); hematuria with urinary tract infections (OR, 33); and gastrointestinal bleeding (OR, 4.1) (Figure [3A](#rth212374-fig-0003){ref-type="fig"}) but not for muscle, joint, or intracranial bleeding (Table [S4](#rth212374-sup-0001){ref-type="supplementary-material"}). Females with PFD had increased risks for excessive bleeding with childbirth/miscarriage (OR, 17) and prolonged (\>7 days) menses (OR, 8.8) (Figure [3B](#rth212374-fig-0003){ref-type="fig"}, Table [S4](#rth212374-sup-0001){ref-type="supplementary-material"}). They also had higher risks than affected males for experiencing excessive bleeding or bruising (OR, 207 vs 87), bruising without trauma (OR, 35 vs 14) and bruising disproportionate to trauma (OR, 26 vs 14) (Figure [3B](#rth212374-fig-0003){ref-type="fig"}, Tables [S5](#rth212374-sup-0001){ref-type="supplementary-material"} and [S6](#rth212374-sup-0001){ref-type="supplementary-material"}). The increased likelihood of a family history of leukemia/bone marrow problems was not evident when families with *RUNX1* mutations were excluded (Table [S4](#rth212374-sup-0001){ref-type="supplementary-material"}).

![Bleeding risk estimates for important mucocutaneous and challenge‐related bleeding symptoms for participants with an uncharacterized platelet function disorder compared to general population controls. Bleeding risks are summarized as odds ratios (ORs) with 95% confidence intervals (CIs) for findings without (A) and with sex differences (B) (additional details in Tables [S4‐S7](#rth212374-sup-0001){ref-type="supplementary-material"}). GI, gastrointestinal](RTH2-4-799-g003){#rth212374-fig-0003}

3.5. Relationships between laboratory findings and bleeding symptoms {#rth212374-sec-0019}
--------------------------------------------------------------------

Analyses for relationships between symptoms and laboratory findings for participants with PFD revealed that reduced MA with collagen was associated with more bruises (median numbers for those with or without reduced MA: 5 vs 2; *P* \< .01) and wound healing problems (OR, 9.3; 95% CI 1.1‐110; *P* \< .04). Among participants with low DG counts, DG counts were significantly lower for those reporting surgical bleeding (1.2 vs 2.2; *P* \< .04).

4. DISCUSSION {#rth212374-sec-0020}
=============

Our primary goals were to evaluate bleeding risks for uncharacterized PFD that impair aggregation responses to multiple agonists and/or cause nonsyndromic DGD, and explore possible relationships between bleeding and MA or DG abnormalities. We excluded well‐characterized and syndromic PFDs, as these PFDs are less common and better understood. We found probable pathogenic *RUNX1* sequence variants in \~9% (2/23) of index cases, verifying that these disorders represent an important PFD subgroup.[^8^](#rth212374-bib-0008){ref-type="ref"}, [^9^](#rth212374-bib-0009){ref-type="ref"} WES failed to find a probable cause of the PFD in most index cases, which is in keeping with other studies.[^9^](#rth212374-bib-0009){ref-type="ref"}, [^28^](#rth212374-bib-0028){ref-type="ref"}, [^29^](#rth212374-bib-0029){ref-type="ref"}, [^30^](#rth212374-bib-0030){ref-type="ref"}, [^31^](#rth212374-bib-0031){ref-type="ref"} We purposely evaluated both index cases and additional family members to minimize potential bias in clinical and laboratory data, noting that index cases had more bleeding but similar laboratory findings to other affected individuals. Aggregation abnormalities were present in the majority of our affected participants (81%), and DGD was present in 30%. Many with DGD (64%) had normal aggregation findings, and 1 had normal ATP release, verifying that these tests do not detect all cases with DGD.[^7^](#rth212374-bib-0007){ref-type="ref"} Unlike unaffected family members and general population controls, our PFD cases had elevated ISTH‐BAT scores, like others with PFD.[^11^](#rth212374-bib-0011){ref-type="ref"}, [^32^](#rth212374-bib-0032){ref-type="ref"} Our PFD cases reported challenge‐related bleeding about as often as reported for severe PFD.[^33^](#rth212374-bib-0033){ref-type="ref"} ISTH‐BAT scores were higher for PFD participants who had prior surgery or wound healing problems, which is interesting, as platelets release mediators that contribute to wound healing.[^34^](#rth212374-bib-0034){ref-type="ref"} Our PFD cohort did not report some bleeding problems (eg, joint and muscle bleeds, spontaneous hematuria) that occur in Quebec platelet disorder,[^35^](#rth212374-bib-0035){ref-type="ref"} suggesting that CHAT‐P might be useful to phenotype PFD. Unlike ISTH‐BAT scores, likelihood estimates allowed us to quantify bleeding while censoring data for those without exposure to certain challenges. Our bleeding risk estimates clarify that uncharacterized PFDs have significantly increased bleeding risks compared to the general population (Figure [3](#rth212374-fig-0003){ref-type="fig"}). Like other studies, females were seen more often than males for bleeding assessment,[^5^](#rth212374-bib-0005){ref-type="ref"}, [^6^](#rth212374-bib-0006){ref-type="ref"}, [^7^](#rth212374-bib-0007){ref-type="ref"}, [^13^](#rth212374-bib-0013){ref-type="ref"}, [^36^](#rth212374-bib-0036){ref-type="ref"} possibly because females with PFD experience more spontaneous and disproportionate bruises, in addition to prolonged menses and childbirth‐related bleeding (Figure [3](#rth212374-fig-0003){ref-type="fig"}). We noted that participants appreciated learning about their estimated bleeding risks, which aided treatment discussions. As many PFD participants reported surgical and dental bleeding only when prophylactic treatment was not given, earlier diagnosis and treatment could improve outcomes, including the need for transfusions.

Our study purposely focused on the commonest type of PFD encountered in hematology practice. While 9% of our index cases (representing 2 families) had probable pathogenic TF mutations affecting *RUNX1*, 1 had no family history of leukemia or myelodysplasia. *RUNX1* mutations alter gene expression,[^19^](#rth212374-bib-0019){ref-type="ref"}, [^37^](#rth212374-bib-0037){ref-type="ref"}, [^38^](#rth212374-bib-0038){ref-type="ref"}, [^39^](#rth212374-bib-0039){ref-type="ref"}, [^40^](#rth212374-bib-0040){ref-type="ref"}, [^41^](#rth212374-bib-0041){ref-type="ref"}, [^42^](#rth212374-bib-0042){ref-type="ref"}, [^43^](#rth212374-bib-0043){ref-type="ref"} and we found reduced expression of *PF4*, *MYL9*, and *ALOX12* in platelets from PFD participants with *RUNX1* haploinsufficiency mutations, with some but not all showing increased *MYH10* transcript and protein levels compared to controls. Accordingly, we caution against analyzing *MYH10* for diagnostic purposes. At present, there is no consensus on when to evaluate PFD cases for TF mutations and ethical concerns have been raised about testing for mutations with other health implications.[^15^](#rth212374-bib-0015){ref-type="ref"}, [^19^](#rth212374-bib-0019){ref-type="ref"}, [^42^](#rth212374-bib-0042){ref-type="ref"} In consideration of these issues, we gave participants the choice of having their physician informed if a potential disease‐causing mutation was found (with the recommendation for further testing by a clinical genetics laboratory), and if the testing of a family uncovered a PFD mutation with other health implications, we used a modified consent form that disclosed this information to recruit additional family members.

Our study provides important evidence that uncharacterized PFD, presenting with impaired aggregation responses and/or nonsyndromic DGD, without a likely a priori cause, are associated with clinically important increased bleeding risks that are relevant to evidence‐based care. Uniquely, we identified that impaired collagen aggregation is associated with more bruising and wound healing problems, and that more severe DGD is associated with surgical bleeding. These interesting associations suggest that platelet‐collagen interactions reduce bruising and promote wound healing, and that platelet DGs (which store polyphosphate and ADP for stimulus‐induced release) help limit surgical bleeding.[^34^](#rth212374-bib-0034){ref-type="ref"}, [^44^](#rth212374-bib-0044){ref-type="ref"}
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